Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Michigan
With
Regeneron Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Physician-diagnosed/managed severe asthma patients that are clinically eligible for dupilumab
Current treatment with a medium-to-high-dose inhaled glucocorticoid (fluticasone propionate at a total daily dose of greater or equal (≥) 440 μg or equipotent equivalent) plus up to at least one additional controller (e.g., a long-acting β2-agonist or leukotriene receptor antagonist)
Asthma that is uncontrolled, as defined by a score on the Asthma Control Test of 19 or lower, or a worsening of asthma in the past year that led to an asthma hospitalization, Emergency Department visit, or 3 days of oral corticosteroids
Severity of asthma that, in the opinion of the subject's asthma care specialist, requires dupilumab for control
For women of childbearing age: agree to use birth control or remain abstinent during the duration of the study.
You may not be if
Patients with diagnosis of other chronic lung diseases (e.g. Chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis, Churg-Strauss syndrome, Allergic bronchopulmonary aspergillosis, etc.)
Current smoker or reported smoking within 1 month of the screening visit (tobacco or any inhaled recreational product)
Greater than 10 total pack-year of cigarette smoking history
Treatment with oral corticosteroids for an asthma exacerbation 1 month prior to screening or during the screening period
Use of any biologic therapy for asthma within the past 3 months
Respiratory or Gastrointestinal illness within 1 month prior to screening or during the screening period
Treatment with antibiotics for acute infections within six weeks prior to screening or during the screening period.
Pregnancy at enrollment or during the study
Known hypersensitivity to dupilumab or its excipients